Company intelligence / Profile preview
Microbion
Bozeman, Montana, United Statesmicrobioncorp.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
MBN‑101 has demonstrated broad-spectrum antibacterial efficacy in vitro against a wide range of pathogens—including CDC priority superbugs—and can prevent and eradicate microbial biofilms. This dual-action mechanism positions it as a potential first-in-class therapy for serious resistant infections. Clinical results to date support continued development but specific trial outcomes are not detailed in the provided sources.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (novel class of antimicrobial/anti-biofilm compounds)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Microbion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microbion.